RSH is part of a very full agenda, but hopefully the audience at BIoshares recognizes the strong operational position the company is in and the enormous commercial potential given the favourable RPM reimbursed market in the US across the chronic diseases RSH now supports post merger with Access.
Getting new investors interested at these entry levels must be attractive with these brokers looking like heroes over the next 12 - 24 months.
RSH is part of a very full agenda, but hopefully the audience at...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
